RXNT Ambient IQ

Graded on the vendor's own argument rather than against it. RXNT markets Ambient IQ's advantage as native integration into a platform built since 1999 and as being backed by 26 years of clinical insights and millions of data points, explicitly contrasting itself with venture backed tools a year or two old. That is a moat is the dataset and the platform claim, which this index grades centrality down for, applied to Reveleer and the credentialing lane.

The module is genuinely generative and it is also sold standalone at a published price, which is the reason to revisit: separate saleability is what earned Sunoh.ai an A. On current positioning the moat is the EHR history, not the model.

The review step is described plainly and in the right order: the AI transcribes and produces a note, the clinician reviews and makes changes, and then signs, with RXNT customers getting a clinical encounter created automatically from the note and presented ready to be signed rather than filed. Signature as the gate rather than as a follow up is the safer of the two patterns this index tracks. Held at B because no acceptance rate, edit burden figure or confidence threshold is published.

No accuracy figure, model card, named models or evaluation methodology located. The headline claim, documentation time reduced by up to 70 percent, uses the unfalsifiable up to construction. One marketing choice worth flagging: RXNT supports its case by citing a 2025 study reporting that physicians reached correct diagnoses in only 20 percent of complex cases while AI assisted tools were several times more accurate. That is a diagnostic accuracy finding about other systems being used to sell a documentation tool, and the two capabilities are not related. Borrowed evidence is not evidence.

Nothing identifies any party in the chain: no model or model family, no foundation model provider, no hosting arrangement and no sub processor list was located in two passes. Recordings are described as encrypted with secure storage, which names the artifact being protected and is more specific than a generic compliance claim, but it says who protects the content rather than who processes it. One workflow feature makes the unanswered questions more pressing than for a capture only product.

The tool supports post visit dictation as well as live capture, so audio exists as a file waiting to be processed rather than only as a stream discarded on completion, and a file persists somewhere until something deletes it. Whatever unnamed parties sit in this chain are therefore holding stored audio rather than transient audio, and no retention schedule is published. Ask whether any third party model provider is invoked, for a sub processor list, and for the retention position on dictated audio specifically rather than on recordings generally.

Named physician testimonials and vendor claims only: documentation reduced by up to 70 percent and providers able to see up to 15 more patients a week, neither with a denominator, cohort or methodology. Inclusion in a magazine's top health technology company list is recognition rather than evaluation. No study, controlled comparison, accuracy benchmark or third party performance rating located.

States that Ambient IQ is built to meet HIPAA standards with encrypted recordings and secure data storage, which is more specific than a generic compliance claim because it names the artifact being protected. Held at B because no retention schedule for recordings or transcripts, no de identification practice and no statement on whether customer data trains models was located. Given that the product supports post visit dictation as well as live capture, audio may persist longer in the workflow than for capture only tools, which makes retention the question to ask.

HIPAA compliance stated for the module, and the parent platform is ONC certified as an electronic health record, which is a separate and genuine certification even though it concerns record system functionality rather than AI. Business associate agreement terms are not published for inspection.

Read the wording carefully, because it is doing less work than it appears to. RXNT states that it hosts all applications and data in SOC 2 Type II certified data centres. That certifies the facility and its operator, not RXNT's own controls, processes or software.

It is a meaningfully weaker claim than holding a SOC 2 Type II report covering the company itself, which is what a health system security review will ask for, and it belongs alongside the other near attestations this index tracks such as SOC 2 aligned and verified by a third party auditor. Graded C rather than Not Rated because a real certification is genuinely present somewhere in the stack. Ask whether RXNT itself holds a report.

No clearance claimed and none required for ambient documentation. No United States device pathway attaches to a note the clinician reviews and signs, and the vendor describes exactly that workflow: start the session, record the discussion, then review and sign the generated note.

This record deserves credit for an express scoping statement most of the category does not make. The company states plainly that the product is not a diagnostic tool and that diagnosis remains in the purview of the provider. Saying so unprompted is the right posture and it is rarer here than it should be.

One thing sits awkwardly beside it and is worth flagging, because claims of intended use are part of how device status gets assessed. The same launch material introduces that disclaimer by citing a 2025 study on diagnostic accuracy, reporting that physicians reached correct diagnoses in only a minority of complex cases while AI assisted tools performed several times better, then states that although this product is not diagnostic it helps bridge the gap. That borrows the credibility of diagnostic AI research to market a documentation product. The disclaimer which follows is accurate and is credited here, but a buyer should notice that the surrounding framing gestures at a benefit the product does not claim to deliver, and a regulator reading marketing for evidence of intended use would notice the same thing.

The product itself is narrow. Transcription and note generation, an encounter summary feature for spotting charting discrepancies, and specialty templates. No coding engine, no decision support module and no patient facing product were located, which keeps the regulatory position simple and is worth recording as a positive rather than as an omission.

United States only, sold both natively inside the vendor's own record system and standalone.

A second search confirms the absence. No fairness statement, no subgroup analysis, no accuracy breakdown by accent, dialect, age or speech characteristic, and no evaluation methodology were located, and no language coverage beyond English is claimed.

The familiar imbalance is present. The time saving is quantified precisely and repeatedly at up to seventy percent, while accuracy is asserted throughout, with claims that the system documents critical details which might otherwise be overlooked and reduces errors and omissions. The efficiency figure has a number attached. The accuracy claim does not.

This record carries a sharper and more specific version of the domain question than a general purpose scribe does, because of what it markets itself for. The vendor names psychiatry and behavioural health among its specialty templates. Those are precisely the encounters where speech recognition meets its hardest conditions. Pressured or disorganised speech, flattened prosody, medication induced dysarthria, long pauses, distress and thought disorder are clinical features of the population being documented rather than noise around it. A scribe that degrades under those conditions degrades specifically for psychiatric patients, and the record it produces is the one that follows them.

English only coverage compounds it. A behavioural health encounter conducted in a patient's second language is already harder to document accurately, and nothing in the workflow reveals to the reviewing clinician where the system struggled.

None of this is exotic to ask about. Peers in this category have submitted note quality to published evaluation against validated documentation quality instruments, so the methods exist and are in use in this segment. The gap is a choice rather than a technical impossibility.

Two passes located no accuracy or error figure, no published limitations and no warranty, indemnity or remediation commitment. The headline claim, documentation time reduced by up to 70 percent, uses the up to construction that is satisfied by any result at all. One marketing choice on this record introduces a claim shape worth naming as a test, because it is more misleading than an absent number.

The vendor supports its case by citing a study reporting that physicians reached correct diagnoses in only a small minority of complex cases while artificial intelligence assisted tools were several times more accurate. That is a finding about diagnostic systems, produced by other parties, deployed to sell a documentation tool, and the two capabilities are unrelated: nothing about a scribe's ability to transcribe and structure an encounter follows from a diagnostic model's performance on complex cases.

Borrowed evidence is not evidence. A reader who takes the citation at face value comes away believing something has been demonstrated about this product when nothing has, and the effect is to import credibility the vendor has not earned rather than merely to omit a measurement. Ask for a performance figure produced on this product, with a definition and a sample.

Two tiers, honestly described, which is the notable part. Inside RXNT the integration is native and produces a signed ready clinical encounter rather than text to move. Outside it, Ambient IQ works standalone and system agnostically by copying the note into any record system, and RXNT says so directly rather than implying parity, even writing that third party integrations elsewhere mean results may vary. Held at B because the deep path exists only within its own platform and the standalone path is transfer based, the shallowest architecture in this index.

Cloud delivered with 24 hour access and mobile applications for iOS and Android, and hosting is described as being in certified data centres, which is more than most vendors say. Held at C because no region, residency option or sub processor detail was located, so a buyer knows the facilities are audited but not where they are.

The clearest commercial disclosure of any EHR vendor in this index, and it is a deliberate strategy rather than an oversight. RXNT publishes its complete price list on its own website, flat and per provider per month, so a buyer can determine what they will pay without a sales call.

Ambient IQ is included at no additional cost for EHR and Full Suite customers with unlimited sessions and no cap on transcription or note creation, and is sold standalone at 75 US dollars a month after a free three month trial. Setup, training, support and mobile apps are stated as included rather than quoted separately, which is where competitors commonly recover margin. It also discloses which features standalone buyers do not receive. Against a category where most vendors publish nothing, this is the reference standard.

Ambulatory across practice sizes from solo providers to multi specialty multi location groups, described as specialty and system agnostic, with typical users including family medicine, paediatrics and urology. Two capabilities widen the fit: custom encounter templates by specialty, and support for both live capture during the visit and post visit dictation, which suits clinicians who cannot record in front of patients. One honest limitation the vendor states itself: the specialty template customisation is available only to EHR and Full Suite customers, not to standalone users. English only.